Amgen/Takeda VEGF Inhibitor Motesanib Faces Setback In NSCLC
This article was originally published in The Pink Sheet Daily
Executive Summary
Enrollment in a Phase III trial in NSCLC patients is suspended after early mortality rates were seen in the treatment arm.